ONTX - Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress | Benzinga
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), ("Onconova", the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract reporting the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced/metastatic squamous cell carcinoma (SCC) will be presented in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2023 Congress taking place October 11-14 in Berlin, Germany.
Presentation Details
| Date: |
| Thursday, October 12, 2023 |
| Time: |
| 4:00-4:15 p.m. in Germany / 10:00-10:15 a.m. ET |
| Abstract Title: |
| Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) Associated Advanced/Metastatic Squamous Cell Carcinoma (SCC) |
| Presenter: |
| Prof. Dr. Johann Bauer, MD University Hospital Salzburg |
| Session: |
| D2T01.3: Late breaking news |